Prokidney CORP Form 4 insider transactions

ProKidney Corp's CEO, Bruce Culleton, reports the acquisition of 1,796,000 employee stock options with an exercise price of $1.23, vesting monthly over four years starting March 1, 2025.

Darin J. Weber, Chief Regulatory Officer of ProKidney Corp., reports the acquisition of stock options to purchase 450,000 Class A Ordinary Shares.

Todd Girolamo, Chief Legal Officer of ProKidney Corp, reports the acquisition of 650,000 employee stock options on March 1, 2025.

James Coulston, CFO of ProKidney Corp., reports the acquisition of 650,000 employee stock options.

Pablo Legorreta and Tolerantia, LLC report changes in beneficial ownership of ProKidney Corp. securities, involving the exchange and distribution of Class A Ordinary Shares.

Director Brian Pereira reports acquisition of Class A Ordinary Shares and derivative securities in ProKidney Corp through transactions including receipt of Class B Ordinary Shares and Common Units.

Darin J. Weber, Chief Regulatory Officer of ProKidney Corp., sold 16,412 Class A Ordinary Shares at $2.5 per share on September 19, 2024, under a pre-arranged 10b5-1 trading plan.

ProKidney Corp's CEO, Bruce Culleton, acquired 500,000 stock options after the company's board certified the achievement of a performance goal.

Jennifer A. Fox, a director of ProKidney Corp., acquired stock options for 9,535 Class A Ordinary Shares on September 3, 2024.

Todd Girolamo, Chief Legal Officer of ProKidney Corp., reports the acquisition and disposition of Class A Ordinary Shares, Class B Ordinary Shares, and Common Units in ProKidney LP on July 31, 2024.

Darin J. Weber, Chief Regulatory Officer of ProKidney Corp., sold 826 shares of Class A Ordinary Shares on July 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Control Empresarial de Capitales S.A. de C.V., associated with the Slim Family, reports acquiring additional Class A Ordinary Shares in ProKidney Corp., increasing their beneficial ownership.

Darin J. Weber, Chief Regulatory Officer of ProKidney Corp., sold 17,238 Class A Ordinary Shares at an average price of $2.8203 on June 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Pablo Legorreta and Tolerantia, LLC report the acquisition of 22,617,909 Class A Ordinary Shares of ProKidney Corp. at $2.42 per share.

Director Jennifer A. Fox received stock options for 62,558 Class A Ordinary Shares in ProKidney Corp.

Director Uma Sinha received stock options for 62,558 Class A Ordinary Shares in ProKidney Corp on May 30, 2024.

Director Pablo G. Legorreta acquired 62,558 stock options in ProKidney Corp. on May 30, 2024.

Director Brian JG Pereira acquired 62,558 stock options in ProKidney Corp. on May 30, 2024.

Director Jimenez Santos Jose Ignacio acquired 62,558 stock options in ProKidney Corp. on May 30, 2024.

Director William F. Doyle acquired 62,558 stock options in ProKidney Corp. on May 30, 2024, according to a Form 4 filing.

Director Alan Lotvin acquired stock options in ProKidney Corp. on May 30, 2024.

Darin J. Weber, Chief Regulatory Officer of ProKidney Corp., sold 17,238 Class A Ordinary Shares on May 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Control Empresarial de Capitales S.A. de C.V., a major shareholder of ProKidney Corp., reports multiple transactions involving Class A Ordinary Shares between March 13 and March 25, 2024.

Darin J. Weber, SVP of Regulatory Development at ProKidney Corp., sold a total of 17,238 Class A Ordinary Shares on April 18 and April 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Darin J. Weber, SVP of Regulatory Development at ProKidney Corp., sold 17,238 shares of Class A Ordinary Shares on April 16, 2024, at a price of $2.5 per share, according to a Form 4 filing.

Darin J. Weber, SVP of Regulatory Development at ProKidney Corp., reports the sale of Class A Ordinary Shares on April 1st and April 12th, 2024, under a pre-arranged trading plan.

EVP of Technical Operations at ProKidney Corp., Ulrich Peter Alfred Ernst, reports acquisition of 335,000 employee stock options.

James Coulston, CFO of ProKidney Corp., was granted 275,000 employee stock options on March 1, 2024, according to a Form 4 filing with the SEC.

Todd C. Girolamo, Chief Legal Officer of ProKidney Corp., received stock options for 534,742 Class A Ordinary Shares.

Darin J. Weber, SVP of Regulatory Development at ProKidney Corp., reports the acquisition of employee stock options.